This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Somatuline Autogel

Ipsen SA

Drug Names(s): Somatuline Depot, lanreotide acetate

Description: Lanreotide is a somatostatin analogue which inhibits the excess release of growth hormone and IGF-1.

Somatostatin is a peptide hormone that regulates the endocrine system and affects neurotransmission and cell proliferation via interaction with G-protein-coupled somatostatin receptors and inhibition of the release of numerous secondary hormones.

Deal Structure: Ipsen and Teijin
In July 2003, Ipsen and Teijin enter into an agreement to development and market four Ipsen products in Japan and a Teijin's anti-gout agent, TMX-67 for the treatment of gout in Europe.

The four products from Ipsen are a Glucagon-like peptide-1 analogue (GLP-1, code name: BIM51077) for which Teijin has been granted co-exclusive rights in Japan, a type 2-receptor selective somatostatin analogue (SSTR-2, code name: BIM23190), a parathyroid hormone 1-34 fragment analogue (PTH, code name: BIM44058), and a sustained-release formulation of a somatostatin analogue (Somatuline Autogel), for which Teijin has been granted exclusive rights in Japan. Teijin will develop the analogues of GLP-1, SSTR-2, PTH and Somatuline Autogel as treatments for type II diabetes, diabetic retinopathy, severe osteoporosis, and acromegaly, respectively.

Ipsen and Tercica
In October 2006, Tercica entered into a worldwide strategic collaboration agreement in endocrinology...See full deal structure in Biomedtracker

Partners: Teijin Pharma Limited


Somatuline Autogel News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug